Clinical Trial Update: The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating golimumab (MK-8259-012) in ankylosing spondylitis, focusing on the incidence of extra-articular manifestations. Results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ankylosing Spondylitis | Phase 4 | Status: COMPLETED | Results posted: 2016-08-03